NIPD Genetics Public Company Limited announced the formal acquisition of 68.3% of its shares for €44.4 million, net of debt, from Medicover Investment BV. As stated in a press release, the acquisition was completed in mid-January 2022.
It is added that with the approval of the acquisition by the Competition Protection Commission (CPC) of the Republic of Cyprus, European healthcare and diagnostic services giant Medicover is increasing its shareholding in NIPD Genetics from 18.9% to 87.2% of the voting rights.
(CNA)
CNA
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
